NLRP3 and COVID-19: Simultaneously, with complement factors known to be activated in COVID-19 (Ma et al. 2021) and also a priming agent for NLRP3 signaling (Niyonzima et al. 2020), the diseased state can be thought as an interplay between IL-1 and complement system.